Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - duloxetine hydrochloride 67.3mg equivalent to duloxetine base 60 mg - modified release capsule - 60 mg - active: duloxetine hydrochloride 67.3mg equivalent to duloxetine base 60 mg excipient: ammonia solution colour mixture white ddb8257w gelatin hypromellose hypromellose acetate succinate indigo carmine ink iron oxide yellow purified talc sodium laurilsulfate sucrose sugar spheres titanium dioxide triethyl citrate

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - tadalafil 20mg - film coated tablet - 20 mg - active: tadalafil 20mg excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 32k97462 purified talc sodium laurilsulfate - adcirca is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - testosterone 2%{relative} - topical solution - 2% w/v - active: testosterone 2%{relative} excipient: ethanol isopropyl alcohol octisalate povidone - androgen replacement therapy for confirmed testosterone deficiency in males

Spojené štáty - angličtina - NLM (National Library of Medicine)

eli lilly and company - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 90 mg - prozac® is indicated for the treatment of: - acute and maintenance treatment of major depressive disorder [see clinical studies (14.1)] . - acute and maintenance treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd) [see clinical studies (14.2)]. - acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe bulimia nervosa [see clinical studies (14.3)] . - acute treatment of panic disorder, with or without agoraphobia [see clinical studies (14.4)]. prozac and olanzapine in combination is indicated for the treatment of: - acute treatment of depressive episodes associated with bipolar i disorder. - treatment resistant depression (major depressive disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). prozac monotherapy is not indicated for the treatment of depressive episodes associated with bipolar i disorder or the treatment of treatm

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg, overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg, overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - insulin lispro 100 u/ml (3.5mg; overage 0-3%);   - suspension for injection - 100 u/ml - active: insulin lispro 100 u/ml (3.5mg; overage 0-3%)   excipient: dibasic sodium phosphate heptahydrate glycerol hydrochloric acid metacresol phenol protamine sulfate sodium hydroxide water for injection zinc oxide - for the treatment of patients with type 1 (iddm) and type 2 (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - prasugrel hydrochloride -

Spojené štáty - angličtina - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Spojené štáty - angličtina - NLM (National Library of Medicine)

rising pharma holdings, inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Spojené štáty - angličtina - NLM (National Library of Medicine)

novel laboratories, inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjÖgren's syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.